Anne Myrka

Anne Myrka

Auto-generated profile, based on publicly available information

Anne Myrka

IPRO Hypoglycemia Coalition, Care Transitions Task Force Member, Albany, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in The Joint Commission Journal on Quality and Patient Safety
Verified
Journal Article
Closed access
DTDarren Triller
Darren Triller
AMAnne Myrka
Anne Myrka
JGJohn Gassler
John Gassler
KRKelly Rudd
Kelly Rudd
PMPatrick D. Meek
Patrick D. Meek
JAJack Ansell
Jack Ansell

21 December 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
Alex C SpyropoulosAlex C Spyropoulos
Alex C Spyropoulos
AMAnne Myrka
Anne Myrka
DTDarren M Triller
Darren M Triller
SRStephen Ragan
Stephen Ragan
CYCollin York
Collin York
TLTi-Kuang Lee
Ti-Kuang Lee
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

28 February 2022 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
MMMedha N. Munshi
Medha N. Munshi
SSSarah L. Sy
Sarah L. Sy
HFHermes J. Florez
Hermes J. Florez
EHElbert S. Huang
Elbert S. Huang
KLKasia J. Lipska
Kasia J. Lipska
DTDarren M. Triller
Darren M. Triller
Introduction Antihyperglycemic agents are significant contributors to adverse drug events, responsible for emergency department visits, hospitalizations, and death. Nationally, the rate of serious hypoglycemic events associated with these agents remains high despite widespread efforts to improve drug safety. Transitions of care between healthcare settings can lead to communication challenges between care professionals and increase the risk of adverse drug events. System-based improvements are needed to assure the safe transitions for patients with diabetes who are on antihyperglycemic agents. The objective of this study was to develop a consensus list of requisite elements that should be communicated between care settings during transitions of patients who are prescribed antihyperglycemic agents. Methods The Island Peer Review Organization (IPRO) Hypoglycemia Coalition identified suboptimal transitions of care as a barrier to improving patient safety and quality of diabetes care. The Coalition formed a multidisciplinary Task Force with experts in the field of diabetes care. The Task Force created a draft list of requisite communication elements through literature review and deliberation on monthly conference calls. A blinded iterative Delphi process was subsequently performed to generate a consensus list of requisite communication elements that participating experts agreed were necessary to safely and effectively assume the management of patients with diabetes upon care transitions. Results The Task Force completed a series of four iterative polls from September 2015 to August 2016, resulting in a final list of 22 requisite communication elements (the Diabetes Management Discharge Communication List), with the elements conceptually categorized into three domains: diagnosis and treatment, factors affecting glycemic control or patient risk, and patient self-management. Conclusions The Diabetes Management Discharge Communication List provides an initial framework for the development of diabetes-specific resources to improve clinical communication between care settings.

1 July 2014 in The Consultant Pharmacist
Verified
Journal Article
Closed access
DTDarren Triller
Darren Triller
SWSusan Wymer
Susan Wymer
KMKaren Morris
Karen Morris
GFGayle Farman
Gayle Farman
AMAnne Myrka
Anne Myrka

18 May 2018 in JMIR Preprints
Verified
Preprint
Open access
Alex C SpyropoulosAlex C Spyropoulos
Alex C Spyropoulos
AMAnne Myrka
Anne Myrka
DTDarren M Triller
Darren M Triller
SRStephen Ragan
Stephen Ragan
CYCollin York
Collin York
TLTi-Kuang Lee
Ti-Kuang Lee
BACKGROUND Anticoagulants are major contributors to preventable adverse drug events, and their optimal management in the periprocedural period is particularly challenging. Traditional methods of disseminating clinical guidelines and tools cannot keep pace with the rapid expansion of available therapeutic agents, approved indications for use, and published medical evidence, so a mobile app, Management of Anticoagulation in the Periprocedural Period (MAPPP), was developed and disseminated to provide clinicians with guidance that reflects the most current medical evidence. OBJECTIVE The objective of this study was to assess the global, national, and state-level acquisition of a mobile app since its initial release and characterize individual episodes of use based on drug selection, procedural bleeding risk, and patient thromboembolic risk. METHODS Data were extracted from a mobile app usage tracker (Google Analytics) to characterize new users and completed episodes temporally (by calendar quarter) and geographically (globally, nationally, and in the targeted US state of New York) for the period between April 1, 2016 and September 30, 2017. RESULTS The app was acquired by 2866 new users in the measurement period, and the users completed nearly 10,000 individual episodes of use. Acquisition and utilization spanned 51 countries globally, predominantly in the United States and particularly in New York State. Warfarin and rivaroxaban were the most frequently selected drugs, and completed episodes most frequently included the selection of high bleeding risk (4888/9963, 49.06%) and high thromboembolic risk categories (4500/9963, 45.17%). CONCLUSIONS The MAPPP app is a successful means of disseminating current guidance on periprocedural anticoagulant use, as indicated by broad global uptake and upward trends in utilization. Limitations in access to provider and patient-specific data preclude objective evaluation of the clinical impact of the app. An ongoing study incorporating app logic into electronic health record systems at participant health systems will provide a more definitive evaluation of the clinical impact of the app logic.